Inmune Bio, Inc.INMB
Price (close)
$2.00
Market cap
$55.3M
P/E
—
Revenue (TTM)
$50,000
Net income
-$18.4M
Dividend yield
—
1-year total return
-1.5%
Net margin
—
Revenue growth
—
Debt / equity
0.74x
What Inmune Bio, Inc. does.
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to
reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction
using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform. RDEB is a devastating pediatric
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $11,000 | $181,000 | $374,000 | $155,000 | $14,000 | $50,000 |
| Net income | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Free cash flow | — | — | — | — | — | -$23.6M |
More on INMB.
- Inmune Bio, Inc. summary
- Inmune Bio, Inc. financial statements
- Inmune Bio, Inc. key metrics
- Inmune Bio, Inc. health scores and style box
- Inmune Bio, Inc. earnings
- Inmune Bio, Inc. dividends
- Inmune Bio, Inc. valuation
- Inmune Bio, Inc. ownership and insiders
- Inmune Bio, Inc. peers
Figures from Inmune Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.